WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 318991
Description: Zalcitabine, also called dideoxycytidine, is a nucleoside analog reverse transcriptase inhibitor (NARTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen. Zalcitabine appears less potent than some other nucleoside RTIs, has an inconvenient three-times daily frequency and is associated with serious adverse events. For these reasons it is now rarely used to treat human immunodeficiency virus (HIV), and it has even been removed from pharmacies entirely in some countries.
MedKoo Cat#: 318991
Chemical Formula: C9H13N3O3
Exact Mass: 211.09569
Molecular Weight: 211.221
Elemental Analysis: C, 51.18; H, 6.20; N, 19.89; O, 22.72
Zalcitabine, purity > 95%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Synonym: NSC606170; NSC 606170; NSC-606170; Zalcitabine; 2′-3′-dideoxycytidine; ddC; dideoxycytidine, Brand name: Hivid.
IUPAC/Chemical Name: 4-amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
InChi Key: WREGKURFCTUGRC-POYBYMJQSA-N
InChi Code: InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
SMILES Code: O=C1N=C(N)C=CN1[C@@H]2O[C@H](CO)CC2
The following data is based on the product molecular weight 211.221 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Carey P. Peripheral neuropathy: zalcitabine reassessed. Int J STD AIDS. 2000 Jul;11(7):417-23. Review. PubMed PMID: 10919481.
2: Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Rev. 2000;(3):CD002038. Review. PubMed PMID: 10908523.
3: Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Rev. 2000;(2):CD002038. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD002038. PubMed PMID: 10796851.
4: Moyle GJ, Gazzard BG. Finding a role for zalcitabine in the HAART era. Antivir Ther. 1998;3(3):125-37. Review. PubMed PMID: 10682130.
5: Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs. 1997 Jun;53(6):1054-80. Review. PubMed PMID: 9179531.
6: Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS. 1997 Mar;11(3):271-9. Review. PubMed PMID: 9147417.
7: Skowron G. ddC (zalcitabine). Adv Exp Med Biol. 1996;394:257-69. Review. PubMed PMID: 8815690.
8: Devineni D, Gallo JM. Zalcitabine. Clinical pharmacokinetics and efficacy. Clin Pharmacokinet. 1995 May;28(5):351-60. Review. PubMed PMID: 7614775.
9: Jablonowski H. Studies of zidovudine in combination with didanosine and zalcitabine. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S52-6. Review. PubMed PMID: 8595509.
10: Shelton MJ, O'Donnell AM, Morse GD. Zalcitabine. Ann Pharmacother. 1993 Apr;27(4):480-9. Review. PubMed PMID: 8097417.
11: Lipsky JJ. Zalcitabine and didanosine. Lancet. 1993 Jan 2;341(8836):30-2. Review. PubMed PMID: 8093278.
12: Whittington R, Brogden RN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs. 1992 Oct;44(4):656-83. Review. PubMed PMID: 1281077.